Dimensional Fund Advisors LP reduced its stake in shares of Core Laboratories (NYSE:CLB) by 0.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 258,788 shares of the oil and gas company’s stock after selling 1,704 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Core Laboratories were worth $25,542,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Janus Henderson Group PLC grew its holdings in shares of Core Laboratories by 1.3% during the 2nd quarter. Janus Henderson Group PLC now owns 5,002 shares of the oil and gas company’s stock worth $506,000 after purchasing an additional 64 shares in the last quarter. ProShare Advisors LLC grew its holdings in shares of Core Laboratories by 2.3% during the 2nd quarter. ProShare Advisors LLC now owns 3,889 shares of the oil and gas company’s stock worth $394,000 after purchasing an additional 87 shares in the last quarter. Moors & Cabot Inc. grew its holdings in shares of Core Laboratories by 1.1% during the 2nd quarter. Moors & Cabot Inc. now owns 15,902 shares of the oil and gas company’s stock worth $1,614,000 after purchasing an additional 168 shares in the last quarter. Advisory Services Network LLC grew its holdings in shares of Core Laboratories by 33.3% during the 2nd quarter. Advisory Services Network LLC now owns 1,365 shares of the oil and gas company’s stock worth $138,000 after purchasing an additional 341 shares in the last quarter. Finally, Balentine LLC grew its holdings in shares of Core Laboratories by 7.1% during the 2nd quarter. Balentine LLC now owns 5,266 shares of the oil and gas company’s stock worth $533,000 after purchasing an additional 347 shares in the last quarter.

Shares of Core Laboratories (NYSE:CLB) opened at $116.00 on Friday. The firm has a market capitalization of $5,090.19, a PE ratio of 63.01 and a beta of 1.56. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.18 and a quick ratio of 1.81. Core Laboratories has a 12 month low of $86.55 and a 12 month high of $124.99.

Core Laboratories (NYSE:CLB) last released its quarterly earnings data on Monday, October 23rd. The oil and gas company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.04. The business had revenue of $166.20 million for the quarter, compared to analyst estimates of $160.94 million. Core Laboratories had a return on equity of 52.89% and a net margin of 12.06%. Core Laboratories’s revenue was up 1.4% compared to the same quarter last year. During the same period last year, the firm posted $0.38 earnings per share. equities analysts predict that Core Laboratories will post 1.99 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, February 16th. Shareholders of record on Friday, January 26th will be given a $0.55 dividend. The ex-dividend date of this dividend is Thursday, January 25th. This represents a $2.20 annualized dividend and a yield of 1.90%. Core Laboratories’s dividend payout ratio is presently 126.44%.

CLB has been the topic of several analyst reports. Scotiabank set a $136.00 target price on Core Laboratories and gave the stock a “hold” rating in a report on Wednesday, October 25th. Zacks Investment Research lowered Core Laboratories from a “hold” rating to a “sell” rating in a research note on Tuesday, September 26th. Loop Capital set a $115.00 price objective on Core Laboratories and gave the company a “buy” rating in a research note on Thursday, December 7th. Piper Jaffray Companies set a $97.00 price objective on Core Laboratories and gave the company a “hold” rating in a research note on Monday, October 23rd. Finally, ABN Amro lowered Core Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, January 9th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the stock. Core Laboratories presently has an average rating of “Hold” and an average target price of $110.20.

TRADEMARK VIOLATION WARNING: “Dimensional Fund Advisors LP Has $25.54 Million Stake in Core Laboratories (CLB)” was posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://theolympiareport.com/2018/01/20/dimensional-fund-advisors-lp-has-25-54-million-stake-in-core-laboratories-clb.html.

About Core Laboratories

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.